1. Guidelines for Pharmacoeconomic Studies

   • Michael F. Drummond

   Guest Editorial 15 November 2012 Pages: 493 - 497

2. Therapeutic Dilemmas

   • Lyn Y. Nishimura
   • Rita Silane

   Leading Article 15 November 2012 Pages: 498 - 505

3. Effects of Capitation on Health of the Chronically III

   • Sylvia K. Reed
   • Kumar Maharaj

   Leading Article 15 November 2012 Pages: 506 - 512

4. The Costs of Rheumatoid Arthritis

   • Saralyn H. Allaire
   • Mark J. Prashker
   • Robert F. Meenan

   Review Article 15 November 2012 Pages: 513 - 522

5. Quality-of-Life Instruments in Hypertension

   • Christopher J. Bulpitt
   • Astrid E. Fletcher

   Review Article 15 November 2012 Pages: 523 - 535

6. Costs of Illness in Cost-Effectiveness Analysis

   • Thomas A. Hodgson

   Review Article 15 November 2012 Pages: 536 - 552

7. Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries

   • Kit Simpson
   • Evi J. Hatzialldreu
   • Anna N.A. Tosteson

   Pharmacoeconomic Drug Evaluation 15 November 2012 Pages: 553 - 562

8. Colfosceril Palmitate

   • Harriet M. Bryson
   • Ruth Whittington

   Pharmacoeconomic Drug Evaluation 15 November 2012 Pages: 563 - 577

9. Measuring Quality of Life in Inflammatory Bowel Disease

   • Douglas A. Drossman

   Current Comment 15 November 2012 Pages: 578 - 580

10. Is Ondansetron Cost Effective?

    • Jacques Bonneterre

    Current Comment 15 November 2012 Pages: 581 - 583

11. How Much Faith Can We Have in Pharmacoeconomic Analyses?

    • Hind T.
    • Sheldon Xiaodong

    Letter to the Editor 15 November 2012 Pages: 584 - 586